Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8157043,maximum concentrations (Cmax),The mean maximum concentrations (Cmax) for the transnasal treatment with and without pretreatment of oxymetazoline were 1.61 and 3.01 ng.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),ng,1.61,16499,DB00935,Oxymetazoline
,8157043,maximum concentrations (Cmax),The mean maximum concentrations (Cmax) for the transnasal treatment with and without pretreatment of oxymetazoline were 1.61 and 3.01 ng.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),ng,3.01,16500,DB00935,Oxymetazoline
,8157043,mean absorption times (MAT),The corresponding mean absorption times (MAT) were 1.34 and 0.23 h.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,1.34,16501,DB00935,Oxymetazoline
,8157043,mean absorption times (MAT),The corresponding mean absorption times (MAT) were 1.34 and 0.23 h.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,0.23,16502,DB00935,Oxymetazoline
,8157043,half-life,"The mean half-life values were 5.95, 6.28, and 5.77 h, for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,5.95,16503,DB00935,Oxymetazoline
,8157043,half-life,"The mean half-life values were 5.95, 6.28, and 5.77 h, for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,6.28,16504,DB00935,Oxymetazoline
,8157043,half-life,"The mean half-life values were 5.95, 6.28, and 5.77 h, for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,5.77,16505,DB00935,Oxymetazoline
,8157043,area under the plasma concentration curve (AUC),"The resulting mean area under the plasma concentration curve (AUC) values were 11.9, 8.6, and 8.07 ng.h.ml-1 for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[h·ng] / [ml],11.9,16506,DB00935,Oxymetazoline
,8157043,area under the plasma concentration curve (AUC),"The resulting mean area under the plasma concentration curve (AUC) values were 11.9, 8.6, and 8.07 ng.h.ml-1 for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[h·ng] / [ml],8.6,16507,DB00935,Oxymetazoline
,8157043,area under the plasma concentration curve (AUC),"The resulting mean area under the plasma concentration curve (AUC) values were 11.9, 8.6, and 8.07 ng.h.ml-1 for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[h·ng] / [ml],8.07,16508,DB00935,Oxymetazoline
,8157043,absolute bioavailability (f),"The estimates for absolute bioavailability (f) of transnasal butorphanol were 69% and 72% when administered with and without oxymetazoline, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,69,16509,DB00935,Oxymetazoline
,8157043,absolute bioavailability (f),"The estimates for absolute bioavailability (f) of transnasal butorphanol were 69% and 72% when administered with and without oxymetazoline, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,72,16510,DB00935,Oxymetazoline
,8157043,CLT,"The mean CLT and Vss were 121 l.h-1 and 791 l, respectively, for the intravenous treatment.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[l] / [h],121,16511,DB00935,Oxymetazoline
,8157043,Vss,"The mean CLT and Vss were 121 l.h-1 and 791 l, respectively, for the intravenous treatment.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),l,791,16512,DB00935,Oxymetazoline
,8157043,absolute bioavailability,"Although the rate of absorption of transnasal butorphanol was affected by oxymetazoline, the absolute bioavailability in rhinitis patients (72%) was similar to that found with the pretreatment of oxymetazoline (69%) and those reported in healthy volunteers.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,72,16513,DB00935,Oxymetazoline
,8157043,absolute bioavailability,"Although the rate of absorption of transnasal butorphanol was affected by oxymetazoline, the absolute bioavailability in rhinitis patients (72%) was similar to that found with the pretreatment of oxymetazoline (69%) and those reported in healthy volunteers.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,69,16514,DB00935,Oxymetazoline
,7719462,flow-rate,An aliquot of reconstituted extract was injected onto a narrow-bore octadecyl reversed-phase column at a flow-rate of 400 microliters/min.,Rapid liquid chromatographic-mass spectrometric assay for oxymetazoline in whole rat blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7719462/),[μl] / [min],400,52724,DB00935,Oxymetazoline
,30786035,Relative bioavailability,"Relative bioavailability compared to the spray formulation was 2.3 (95% confidence interval [CI]: 1.6-3.2), with slow absorption from the mucosal surface (absorption half-life 64 minutes; 95% CI: 44-90).",Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30786035/),,2.3,61239,DB00935,Oxymetazoline
,30786035,absorption half-life,"Relative bioavailability compared to the spray formulation was 2.3 (95% confidence interval [CI]: 1.6-3.2), with slow absorption from the mucosal surface (absorption half-life 64 minutes; 95% CI: 44-90).",Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30786035/),min,64,61240,DB00935,Oxymetazoline
,20669329,S(50),"The derived S(50) and V(max) values were 2.42 ± 0.40 mM and 8.69 ± 0.58 pmole/(min mg of protein), respectively, and maximum clearance (CL(max)) was 3.61 L/min/mg.",Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669329/),mM,2.42,98325,DB00935,Oxymetazoline
,20669329,V(max),"The derived S(50) and V(max) values were 2.42 ± 0.40 mM and 8.69 ± 0.58 pmole/(min mg of protein), respectively, and maximum clearance (CL(max)) was 3.61 L/min/mg.",Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669329/),[pmole] / [mg·min],8.69,98326,DB00935,Oxymetazoline
,20669329,maximum clearance (CL(max)),"The derived S(50) and V(max) values were 2.42 ± 0.40 mM and 8.69 ± 0.58 pmole/(min mg of protein), respectively, and maximum clearance (CL(max)) was 3.61 L/min/mg.",Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669329/),[l] / [mg·min],3.61,98327,DB00935,Oxymetazoline
,20669329,K(m),"The derived K(m) and V(max) values were 2.53 ± 1.03 mM and 54.18 ± 16.92 pmole/(min mg of protein), respectively, and intrinsic clearance (CL(int)) was 21.41 L/(min mg).",Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669329/),mM,2.53,98328,DB00935,Oxymetazoline
,20669329,V(max),"The derived K(m) and V(max) values were 2.53 ± 1.03 mM and 54.18 ± 16.92 pmole/(min mg of protein), respectively, and intrinsic clearance (CL(int)) was 21.41 L/(min mg).",Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669329/),[pmole] / [mg·min],54.18,98329,DB00935,Oxymetazoline
,20669329,intrinsic clearance (CL(int)),"The derived K(m) and V(max) values were 2.53 ± 1.03 mM and 54.18 ± 16.92 pmole/(min mg of protein), respectively, and intrinsic clearance (CL(int)) was 21.41 L/(min mg).",Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669329/),[l] / [mg·min],21.41,98330,DB00935,Oxymetazoline
above,22855901,oxygen saturation,Mean oxygen saturation remained above 99 percent.,The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: preliminary findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22855901/),%,99,113429,DB00935,Oxymetazoline
,22855901,half-life,"Oxymetazoline concentrations from the two-times-MRD administration were approximately 50 percent greater than those from the MRD administration, with a half-life of 1.72 to 2.32 hours.",The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: preliminary findings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22855901/),h,1.72 to 2.32,113430,DB00935,Oxymetazoline
,27436060,ka,The final oxymetazoline parameter estimates were ka 4.41 h-1 ; peripheral volume 418 L; clearance 66.4 L/h; central volume 6.97 L; and intercompartmental clearance 419 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),1/[h],4.41,143067,DB00935,Oxymetazoline
,27436060,peripheral volume,The final oxymetazoline parameter estimates were ka 4.41 h-1 ; peripheral volume 418 L; clearance 66.4 L/h; central volume 6.97 L; and intercompartmental clearance 419 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),l,418,143068,DB00935,Oxymetazoline
,27436060,clearance,The final oxymetazoline parameter estimates were ka 4.41 h-1 ; peripheral volume 418 L; clearance 66.4 L/h; central volume 6.97 L; and intercompartmental clearance 419 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),[l] / [h],66.4,143069,DB00935,Oxymetazoline
,27436060,central volume,The final oxymetazoline parameter estimates were ka 4.41 h-1 ; peripheral volume 418 L; clearance 66.4 L/h; central volume 6.97 L; and intercompartmental clearance 419 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),l,6.97,143070,DB00935,Oxymetazoline
,27436060,intercompartmental clearance,The final oxymetazoline parameter estimates were ka 4.41 h-1 ; peripheral volume 418 L; clearance 66.4 L/h; central volume 6.97 L; and intercompartmental clearance 419 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),[l] / [h],419,143071,DB00935,Oxymetazoline
,27436060,ka,The final PBBA parameter estimates were ka 8.51 h-1 ; peripheral volume 32.0 L; clearance 16.7 L/h; central volume 29.8 L; and intercompartmental clearance 2.43 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),1/[h],8.51,143072,DB00935,Oxymetazoline
,27436060,peripheral volume,The final PBBA parameter estimates were ka 8.51 h-1 ; peripheral volume 32.0 L; clearance 16.7 L/h; central volume 29.8 L; and intercompartmental clearance 2.43 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),l,32.0,143073,DB00935,Oxymetazoline
,27436060,clearance,The final PBBA parameter estimates were ka 8.51 h-1 ; peripheral volume 32.0 L; clearance 16.7 L/h; central volume 29.8 L; and intercompartmental clearance 2.43 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),[l] / [h],16.7,143074,DB00935,Oxymetazoline
,27436060,central volume,The final PBBA parameter estimates were ka 8.51 h-1 ; peripheral volume 32.0 L; clearance 16.7 L/h; central volume 29.8 L; and intercompartmental clearance 2.43 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),l,29.8,143075,DB00935,Oxymetazoline
,27436060,intercompartmental clearance,The final PBBA parameter estimates were ka 8.51 h-1 ; peripheral volume 32.0 L; clearance 16.7 L/h; central volume 29.8 L; and intercompartmental clearance 2.43 L/h for a 70-kg subject.,Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436060/),[l] / [h],2.43,143076,DB00935,Oxymetazoline
,23458227,Cmax,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[pg] / [ml],453.0,181662,DB00935,Oxymetazoline
,23458227,Cmax,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[pg] / [ml],467.8,181663,DB00935,Oxymetazoline
,23458227,AUCt,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,292.3",181664,DB00935,Oxymetazoline
,23458227,AUCt,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,325.4",181665,DB00935,Oxymetazoline
,23458227,AUC0-∞,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,430.6",181666,DB00935,Oxymetazoline
,23458227,AUC0-∞,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,387",181667,DB00935,Oxymetazoline
,23458227,tmax,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),,20,181668,DB00935,Oxymetazoline
,23458227,AUC0-∞,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],1,181669,DB00935,Oxymetazoline
,23458227,AUC0-∞,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],362.4,181670,DB00935,Oxymetazoline
,23458227,rate of absorption (tmax,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),min,53,181671,DB00935,Oxymetazoline
,23458227,Cmax,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[pg] / [ml],235.3,181672,DB00935,Oxymetazoline
≤,29462230,maximum observed plasma concentrations,"Mean maximum observed plasma concentrations were ≤115 pg/mL across all groups; the highest mean values for area under the plasma concentration-time curve from time 0 to 24 hours following once- and twice-daily administration of oxymetazoline 1.5% were 1680 pg•h/mL and 2660 pg•h/mL, respectively.",Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462230/),[pg] / [ml],115,220643,DB00935,Oxymetazoline
,29462230,area under the plasma concentration-time curve from time 0 to 24 hours,"Mean maximum observed plasma concentrations were ≤115 pg/mL across all groups; the highest mean values for area under the plasma concentration-time curve from time 0 to 24 hours following once- and twice-daily administration of oxymetazoline 1.5% were 1680 pg•h/mL and 2660 pg•h/mL, respectively.",Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462230/),[h·pg] / [ml],1680,220644,DB00935,Oxymetazoline
,29462230,area under the plasma concentration-time curve from time 0 to 24 hours,"Mean maximum observed plasma concentrations were ≤115 pg/mL across all groups; the highest mean values for area under the plasma concentration-time curve from time 0 to 24 hours following once- and twice-daily administration of oxymetazoline 1.5% were 1680 pg•h/mL and 2660 pg•h/mL, respectively.",Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462230/),[h·pg] / [ml],2660,220645,DB00935,Oxymetazoline
